IL-17-Related Pathways and Myeloid Cell Function are Involved in the Mechanism of Sublingual Immunotherapy with Artemisia annua for Seasonal Allergic Rhinitis
机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Beijing 100005, China研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[4]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children首都医科大学附属北京儿童医院[5]Rare Disease Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China首都医科大学附属北京儿童医院[6]Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China[7]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
The mechanisms underlying immune tolerance induction during sublingual immunotherapy (SLIT) of seasonal allergic rhinitis (SAR) remain insufficiently understood. This study aimed to investigate the molecular and immunological process involved in SLIT. RNA sequencing (RNA-seq) and bioinformatics analyses were performed to examine the functions of differentially expressed genes (DEGs) in leukocytes from 11 SAR patients at three time points: baseline, peak pollen phase (PPP), and end-of-treatment. Patients received a 4-month SLIT course with Artemisia annua (A. annua) extract (n = 5) or placebo (n = 6). Plasma cytokine levels were measured in a validation cohort of 15 SAR patients (9 in the SLIT group and 6 in the placebo group) using Luminex assays. The results showed that A. annua SLIT inhibited the upregulation of IL-17A-associated pathways and the expression of inflammatory mediators, including CXCL1, CCL7, and PLPP3, while enhancing myeloid immune cell function by increasing the expression of CD36, TYROBP, FCGR1A, and FCER1G. Additionally, A. annua SLIT reactivated myeloid immune cell-associated genes that were downregulated during PPP and significantly reduced IL-17A and GRO-beta levels in plasma, compared to the placebo group. These findings suggest that A. annua SLIT alleviates SAR by modulating IL-17A pathways, reducing inflammatory responses, and enhancing myeloid immune cell function.
基金：
National Natural Science Foundation of China [82271139, 82371115, 81970850, 82471139]; National Key R&D Program of China [2022YFC2504100]; Program for Changjiang Scholars and Innovative Research Team [IRT13082]; China Postdoctoral Science Foundation [2024M752006]; Beijing New-Star Plan of Science and Technology [20230484476]; Beijing Hospitals Authority Youth Programme [QML20230201]; High Level Public Health Technical Talent Training Plan [Lingjunrencai-02-09]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-022]
第一作者机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Beijing 100005, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of New Medicine and Diagnostic Technology Research for Nasal Disease, Beijing 100005, China[4]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children[5]Rare Disease Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China[7]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
推荐引用方式(GB/T 7714)：
Zhao Yan,Mei Song,Yao Shuang,et al.IL-17-Related Pathways and Myeloid Cell Function are Involved in the Mechanism of Sublingual Immunotherapy with Artemisia annua for Seasonal Allergic Rhinitis[J].CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY.2025,68(1):doi:10.1007/s12016-025-09067-w.
APA：
Zhao, Yan,Mei, Song,Yao, Shuang,Cai, Shiru,Zhang, Peng...&Zhang, Luo.(2025).IL-17-Related Pathways and Myeloid Cell Function are Involved in the Mechanism of Sublingual Immunotherapy with Artemisia annua for Seasonal Allergic Rhinitis.CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY,68,(1)
MLA：
Zhao, Yan,et al."IL-17-Related Pathways and Myeloid Cell Function are Involved in the Mechanism of Sublingual Immunotherapy with Artemisia annua for Seasonal Allergic Rhinitis".CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 68..1(2025)
：
医学